VEA
BOLD

Virtus ETF Advisers’s Audentes Therapeutics, Inc BOLD Stock Holding History

Virtus ETF Advisers’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-6,682
Closed -$188K – 526
2019
Q3 		$188K Sell
6,682
-371
-5% -$12.7K 0.04% 258
2019
Q2 		$267K Sell
7,053
-4,663
-40% -$179K 0.06% 262
2019
Q1 		$457K Sell
11,716
-1,468
-11% -$42.1K 0.97% 32
2018
Q4 		$281K Buy
13,184
+1,053
+9% +$27.2K 0.05% 136
2018
Q3 		$480K Sell
12,131
-8,679
-42% -$324K 0.05% 132
2018
Q2 		$795K Sell
20,810
-5,308
-20% -$197K 0.7% 32
2018
Q1 		$785K Buy
26,118
+14,220
+120% +$481K 0.68% 76
2017
Q4 		$372K Buy
+11,898
New +$327K 0.47% 69

Other funds holding BOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Virtus ETF Advisers's BOLD Position: Q4 2019 in Review

Virtus ETF Advisers sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2019, closing a stake of 6,682 shares — an estimated $188K sold.

Virtus ETF Advisers first reported a position in BOLD in Q4 2017 and held it in 8 quarters. The position peaked at $795K in Q2 2018. 188 funds tracked by Wall St. Rank hold BOLD as of Q4 2019.

  • Virtus ETF Advisers reported no remaining Audentes Therapeutics, Inc position as of Q4 2019 after selling out during the quarter.
  • Virtus ETF Advisers sold 6,682 Audentes Therapeutics, Inc shares in Q4 2019, an estimated $188K.
  • Virtus ETF Advisers first reported a position in Audentes Therapeutics, Inc in Q4 2017 and held it in 8 quarters.
  • Virtus ETF Advisers's Audentes Therapeutics, Inc position peaked at $795K in Q2 2018.
  • 188 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2019.

Based on Virtus ETF Advisers's 13F filing for Q4 2019, filed 13 Feb 2020.